• 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud K. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348: 153541.
  • 2
    Russell RG. Bisphosphonates. The first 40 years. Bone. 2011; 49: 219.
  • 3
    Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004; 114: 62333.
  • 4
    Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int. 2004; 94: 16470.
  • 5
    Guise TA. Antitumor effects of bisphosphonates. Promising preclinical evidence. Cancer Treat Rev. 2008; 34(Suppl 1): S1924.
  • 6
    Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.
  • 7
    Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol. 2010; 28: 357781.
  • 8
    Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol. 2011; 29: 114650.
  • 9
    Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010; 102: 799802.
  • 10
    Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010; 304: 65763.
  • 11
    Lin TC, Yang CY, Kao Yang YH, Lin SJ. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011; 90: 10916.
  • 12
    Chiang CH, Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. Association between Mycoplasma pneumonia and increased risk of ischemic stroke: a nationwide study. Stroke. 2011; 42: 29403.
  • 13
    Huang CC, Chan WL, Chen YC, Chen TJ, Chou KT, Lin SJ, Chen JW, Leu HB. Statin use in patients with asthma: a nationwide population-based study. Eur J Clin Invest. 2011; 41: 50712.
  • 14
    Huang CC, Chan WL, Chen YC, Chen TJ, Lin SJ, Chen JW, Leu HB. Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension. Am J Cardiol. 2011; 107: 102833.
  • 15
    Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol. 2002; 29: 3342.
  • 16
    Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002; 302: 105561.
  • 17
    Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, Lane DS, Manson JE, Snetselaar L, Yasmeen S, O'Sullivan MJ, Safford M, Hendrix SL, Wallace RB. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol. 2010; 28: 358290.
  • 18
    Abrahamsen B, Pazianas M, Eiken P, Russell RG, Eastell R. Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res. Epub 2011 Nov 23. DOI: 10.1002/jbmr.1481.
  • 19
    Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG. Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish national register based cohort study. Osteoporos Int. Epub 2012 Mar 6.
  • 20
    Cardwell CR, Abnet CC, Veal P, Hughes CM, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of cancer. Int J Cancer. Epub 2011 Dec 8. DOI: 10.1002/ijc.27389.
  • 21
    Chow SN, Huang CC, Lee YT. Demographic characteristics and medical aspects of menopausal women in Taiwan. J Formos Med Assoc. 1997; 96: 80611.
  • 22
    Zhang Y, Felson DT, Ellison RC, Kreger BE, Schatzkin A, Dorgan JF, Cupples LA, Levy D, Kiel DP. Bone mass and the risk of colon cancer among postmenopausal women: the Framingham study. Am J Epidemiol. 2001; 153: 317.
  • 23
    McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH. Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008; 122: 187984.
  • 24
    Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009; 360: 178990; 1791–2.
  • 25
    Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet. 1991 Aug 10; 338(8763): 3558.